Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3187642 | 1.00 | HIF1A (0.32) | HIF1A | |
| SCHEMBL1784052 | 0.79 | HIF1A (0.40) | HIF1A | |
| SCHEMBL1153789 | 0.79 | — | — | |
| SCHEMBL3193176 | 0.78 | — | — | |
| SCHEMBL3193185 | 0.78 | — | — | |
| SCHEMBL17381336 | 0.75 | ALDH1A1 (0.42) | HIF1A | |
| SCHEMBL873382 | 0.75 | ALOX15 (0.53) | — | |
| SCHEMBL3183864 | 0.75 | ALOX15 (0.53) | — | |
| SCHEMBL10439570 | 0.75 | — | — | |
| SCHEMBL1783631 | 0.73 | ALDH1A1 (0.43) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022500-A1 | Macrocyclic Lactams and Pharmaceutical Use Thereof | NOVARTIS AG | 2010-01-28 | — | — | US | disclosed |
| US-7612055-B2 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2007-03-29 | — | — | US | disclosed |
| CN-1902182-A | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2007-01-24 | — | — | CN | disclosed |
| EP-1682521-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005049585-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | RPS11, MRPL21, RPS4Y1 | HIF1A 4861/4885 |
| US-20100022500-A1 | Macrocyclic Lactams and Pharmaceutical Use Thereof | RPS11, MRPL21, RPS4Y1 | HIF1A 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.